Presentation

Modern oncology research demands more than genomic or transcriptomic snapshots. To truly understand tumor biology, drug developers need visibility into what’s happening at the surface—the proteins that determine how tumors interact, respond, and resist therapy.

In this talk from BiotechX USA 2025, Mike Ritchie, Chief Commercial Officer at Champions Oncology, explores how cell surface proteomics, integrated within Champions’ multi-omic data ecosystem, is unlocking new opportunities for drug target identification, ADC development, and machine learning modeling. Through real-world case studies, he demonstrates how this platform resolves the limitations of RNA and whole-cell proteomic data, providing the translational depth that discovery programs need to move faster and smarter.

What You’ll Learn

• How cell surface proteomics provides a more accurate picture of tumor biology than whole-cell or RNA-based profiling
• Why patient-derived xenograft (PDX) models are uniquely suited for generating biologically and clinically relevant surfaceome data
• The computational framework behind Champions’ multi-omic data integration for AI and ML applications in oncology
• Case studies demonstrating how Trop2 and Cadherin-17 surface expression profiles reveal new insights for ADC development
• The QC and enrichment methodologies used to achieve unmatched data precision and interpretability
• How next-generation perturbation studies are shaping the future of functionalized, AI-powered tumor datasets

Watch the full presentation from BiotechX USA 2025

Gain access to Mike Ritchie’s complete talk and downloadable slide deck to see how Champions Oncology is transforming oncology research through advanced cell surface proteomics and multi-omic integration.

Complete the form to watch now